Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | Director | May 27, 2011 | May 31, 2011 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date May 27, 2011 · Filed May 31, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 10,329.0621 |
Reported balance
After 2011-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2011-05-27 · Grant · Acquired 4,142.5021 · Balance 10,329.0621 F1: 1-for-1 F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3: Holdings include shares acquired in dividend reinvestment transactions. |
| Common StockSEC Table I · non-derivative | Direct | 4,034 |
Reported balance
Holding disclosure · report date 2011-05-27 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,034 |
Filing footnotes · ownership attribution and instrument terms
F1: 1-for-1
F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
F3: Holdings include shares acquired in dividend reinvestment transactions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2011 Filed May 31, 2011 14:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 4,142.5021 | $36.21 | $150,000.00 |
DisclosureSEC source: 0001225208-11-015337 · doc4.xml · derivative · entry 2 JACOBSON HARRY R · CIK 0001255835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,329.0621 Underlying: Common Stock · 4,142.5021 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 13, 2010 Filed Aug 17, 2010 18:18 UTC | Merck & Co., Inc. MRK · Entity 2807 | OtherPreferred Stock | 44 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-019349 · doc4.xml · nonDerivative · entry 2 JACOBSON HARRY R · CIK 0001255835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The reported securities were called for redemption by the issuer. Each share of preferred stock was converted into 4.6719 shares of Merck common stock and $85.06 in cash. Any fractional share holdings were paid in cash. Read SEC document |
| August 13, 2010 Filed Aug 17, 2010 18:18 UTC | Merck & Co., Inc. MRK · Entity 2807 | OtherCommon Stock | 205 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-019349 · doc4.xml · nonDerivative · entry 1 JACOBSON HARRY R · CIK 0001255835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,034 F1 · price: The reported securities were called for redemption by the issuer. Each share of preferred stock was converted into 4.6719 shares of Merck common stock and $85.06 in cash. Any fractional share holdings were paid in cash. Read SEC document |
| August 04, 2010 Filed Aug 6, 2010 14:52 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $35.19 | $0.00 |
DisclosureSEC source: 0001225208-10-018701 · doc4.xml · derivative · entry 3 JACOBSON HARRY R · CIK 0001255835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2020-08-03 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning August 4, 2011. Read SEC document |
| May 28, 2010 Filed Jun 1, 2010 19:58 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 1,632.5319 | $33.69 | $55,000.00 |
DisclosureSEC source: 0001225208-10-014283 · doc4.xml · derivative · entry 3 JACOBSON HARRY R · CIK 0001255835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,930.3359 Underlying: Common Stock · 1,632.5319 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001225208-09-021811 · doc4.xml · derivative · entry 5 JACOBSON HARRY R · CIK 0001255835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2019-04-30 F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $38.04 | $0.00 |
DisclosureSEC source: 0001225208-09-021811 · doc4.xml · derivative · entry 4 JACOBSON HARRY R · CIK 0001255835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2018-04-29 F4 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 4,211.4175 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021811 · doc4.xml · derivative · entry 3 JACOBSON HARRY R · CIK 0001255835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,211.4175 Underlying: Common Stock · 4,211.4175 shares Expires not disclosed F3 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions. F3 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions. F3 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | Disposition to issuerPreferred Stock | 34 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021811 · doc4.xml · nonDerivative · entry 2 JACOBSON HARRY R · CIK 0001255835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44 F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:44 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 3,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021811 · doc4.xml · nonDerivative · entry 1 JACOBSON HARRY R · CIK 0001255835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,829 F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.